Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: A crossover study

Journal of Clinical Psychiatry

Volumn 70, Issue 7, 2009, Pages 958-966

  Chenu, Franck ^a   Batten, Lisa A ^a   Zernig, Gerald ^b   Ladstaetter, Elisabeth ^b   Hébert, Chantal ^a   Blier, Pierre ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DESVENLAFAXINE; GENERIC DRUG; VENLAFAXINE;

AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ERUPTION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ENERGY; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NERVOUSNESS; OPEN STUDY; PHARMACOKINETICS; PILOT STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; THOUGHT DISORDER; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

AREA UNDER CURVE; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CITALOPRAM; CROSS-OVER STUDIES; CYCLOHEXANOLS; DRUGS, GENERIC; HUMANS; MALE; SEROTONIN UPTAKE INHIBITORS; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 68049129708     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05315     Document Type: Article

References (22)

1. Borgheini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003;25(6):1578-1592
2. Roger SD. Biosimilars: how similar or dissimilar are they? Nephrology (Carlton) 2006;11(4):341-346
3. Opelz G. CTS, Collaborative Transplant Study, Newsletter 1: 2001. http://www.ctstransplant.org. Accessed January 5, 2007
4. Qazi YA, Forrest A, Tornatore K, et al. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function. Clin Transplant 2006;20(3):313-317
5. Kovarik JM, Curtis JJ, Hricik DE, et al. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Transplant Proc 2006;38(10):3456-3458
6. Kluznik JC, Walbek NH, Farnsworth MG, et al. Clinical effects of a randomized switch of patients from clozaril to generic clozapine. J Clin Psychiatry 2001;62(suppl 5):14-17
7. Rosenthal J, Kong B, Jacobs L, et al. Did a switch to a generic antidepressant cause relapse? J Fam Pract 2008;57(2):109-114
8. Van Ameringen M, Mancini C, Patterson B, et al. Symptom relapse following switch from Celexa to generic citalopram: an anxiety disorders case series. J Psychopharmacol 2007;21(5):472-476
9. Marzo A. Open questions on bioequivalence: an updated reappraisal. Curr Clin Pharmacol 2007;2(2):179-189
10. Vial J, Cohen M, Sassiat P, et al. Pharmaceutical quality of docetaxel generics versus originator drug product: a comparative analysis. Curr Med Res Opin 2008;24(7):2019-2033
11. Bolton S. Bioequivalence studies for levothyroxine. AAPS J 2005;7(1):E47-E53
12. Poo JL, Galan JF, Rosete A, et al. Bioavailability of two single-dose oral formulations of omeprazole 20 mg: an open-label, randomized sequence, two-period crossover comparison in healthy Mexican adult volunteers. Clin Ther 2008;30(4):693-699
13. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008;300(21):2514-2526
14. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Research Version, Nonpatient Edition (SCID-I/NP). New York, Biometrics Research, New York State Psychiatric Institute, 1997
15. Klier CM, Mossaheb N, Saria A, et al. Pharmacokinetics and elimination of quetiapine, venlafaxine, and trazodone during pregnancy and postpartum. J Clin Psychopharmacol 2007;27(6):720-722
16. Conduct and Analysis of Bioavailability and Bioequivalence Studies-Part B: Oral Modified Release Formulations. Health Canada Web site. p. 38. Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/bio/bio-b- eng.php. Accessed June 9, 2009
17. Effexor [product monograph]. Wyeth Canada. www.wyeth.ca/en/products/ Product%20Monographs%20PDFs/Effexor%20 PRODUCT%20MONOGRAPH%2010Jan07.pdf. Accessed on June 2, 2009
18. Entsuah R, Chitra R. A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Psychopharmacol Bull 1997;33(4):671-676
19. Cunningham LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin Psychiatry 1997;9(3):157-164
20. Wellington K, Perry CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs 2001;15(8):643-669
21. Novo-venlafaxine [product monograph]. Novopharm: Toronto, Ontario, Canada: 2006
22. LeLorier J, Duh MS, Paradis PE, et al. Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. Curr Med Res Opin 2008;24(4):1069-1081